Cas no 63329-53-3 (Lobenzarit)
Lobenzarit Chemical and Physical Properties
Names and Identifiers
-
- Lobenzarit
- 4-Chloro-2,2'-iminodibenzoic acid
- 2-[(2-Carboxyphenyl)amino]-4-chlorobenzoic acid
- 2-(2-carboxyphenylamino)-4-chlorobenzoic acid
- 4-Chloro-2-(2-carboxyphenylamino)benzoic acid
- 5-chloro-2'-carboxydiphenylamine-2-carboxylic acid
- Carfenil
- N-(2-carboxyphenyl)-4-chloranthranilic acid disodium
- N-(2-carboxyphenylamino)-4-chlorobenzoic acid
- N-2'-carboxyphenyl-4-chloroanthranilic acid
- F75214
- UNII-915EE91P39
- AS-71902
- LOBENZARIT [WHO-DD]
- 4-chloro-2,2'-iminodibenzoate
- Q6663655
- Lobenzaritum
- BDBM50591384
- 2-(2-carboxyanilino)-4-chlorobenzoic acid
- HY-124411
- LOBENZARIT [MI]
- Lobenzarit [INN]
- 111GE011
- CHEMBL1986706
- 2-[(2-carboxyphenyl)amino]-4-chloranyl-benzoic acid
- 4-Chlor-2,2'-iminodibenzoesaiure
- SCHEMBL187951
- Benzoic acid, 2-((2-carboxyphenyl)amino)-4-chloro-
- DTXSID20212709
- CHEBI:135215
- AKOS037647002
- Lobenzaritum [INN-Latin]
- A834330
- 915EE91P39
- 2-((2-carboxyphenyl)amino)-4-chlorobenzoic acid
- FT-0630737
- 63329-53-3
- lobenzart
- Lobenzaritum (INN-Latin)
- DB-054458
- DTXCID00135200
- N-(2-carboxyphenyl)-4-chloroanthranilic acid
- BRD-K55847762-304-01-7
- disodium 2-[(2-carboxylatophenyl)amino]-4-chlorobenzoate
- CCA lobenzarit
- BENZOIC ACID, 2-[(2-CARBOXYPHENYL)AMINO]-4-CHLORO-, DISODIUM SALT
-
- Inchi： 1S/C14H10ClNO4/c15-8-5-6-10(14(19)20)12(7-8)16-11-4-2-1-3-9(11)13(17)18/h1-7,16H,(H,17,18)(H,19,20)
- InChI Key： UGDPYGKWIHHBMB-UHFFFAOYSA-N
- SMILES： ClC1C=CC(C(=O)O)=C(C=1)NC1C=CC=CC=1C(=O)O
Computed Properties
- Exact Mass: 291.03000
- Monoisotopic Mass: 334.993725
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 3
- Hydrogen Bond Acceptor Count: 5
- Heavy Atom Count: 20
- Rotatable Bond Count: 4
- Complexity: 376
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- Tautomer Count: 7
- XLogP3: nothing
- Topological Polar Surface Area: 92.3
Experimental Properties
- Color/Form: Crystallization.
- Density: 1.515
- Melting Point: >306°
- Boiling Point: 481 °C at 760 mmHg
- Flash Point: 481 °C at 760 mmHg
- Refractive Index: 1.699
- PSA: 86.63000
- LogP: 3.55300
Lobenzarit Security Information
- Hazardous Material transportation number：UN 3261 8/PG 2
- WGK Germany：3
- Safety Instruction： S26; S27; S28
-
Hazardous Material Identification：
- Toxicity：LD50 in male, female rats (mg/kg): 2100, 2600 orally (Tanemura)
- Packing Group：II
- Hazard Level：8
- Safety Term：8
- Packing Group：II
- Risk Phrases：R34
Lobenzarit Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | L471220-100mg |
Lobenzarit |
63329-53-3 | 100mg |
$144.00 | 2023-05-18 | ||
| TRC | L471220-500mg |
Lobenzarit |
63329-53-3 | 500mg |
$552.00 | 2023-05-18 | ||
| TRC | L471220-1g |
Lobenzarit |
63329-53-3 | 1g |
$ 800.00 | 2023-09-07 | ||
| TRC | L471220-5g |
Lobenzarit |
63329-53-3 | 5g |
$3829.00 | 2023-05-18 | ||
| MedChemExpress | HY-124411-5mg |
Lobenzarit |
63329-53-3 | 99.42% | 5mg |
￥1150 | 2025-04-16 | |
| MedChemExpress | HY-124411-10mg |
Lobenzarit |
63329-53-3 | 99.42% | 10mg |
￥1850 | 2025-04-16 | |
| MedChemExpress | HY-124411-25mg |
Lobenzarit |
63329-53-3 | 99.42% | 25mg |
￥3700 | 2025-04-16 | |
| MedChemExpress | HY-124411-50mg |
Lobenzarit |
63329-53-3 | 99.42% | 50mg |
￥5900 | 2025-04-16 | |
| TRC | L471220-1000mg |
Lobenzarit |
63329-53-3 | 1g |
$959.00 | 2023-05-18 | ||
| SHENG KE LU SI SHENG WU JI SHU | sc-279281-500 mg |
Lobenzarit, |
63329-53-3 | 500MG |
￥5,265.00 | 2023-07-11 |
Lobenzarit Suppliers
Audited Supplier
Audited Supplier
Lobenzarit Related Literature
-
Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
-
Eunice Y.-L. Hui,Bhimsen Rout,Yaw Sing Tan,Kok-Ping Chan,Charles W. Johannes Org. Biomol. Chem., 2018,16, 389-392
-
Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408
-
Jieun Kim,Han-Saem Park,Tae-Hee Kim,Sung Yeol Kim,Hyun-Kon Song Phys. Chem. Chem. Phys., 2014,16, 5295-5300
Additional information on Lobenzarit
Comprehensive Overview of Lobenzarit (CAS No. 63329-53-3): Mechanism, Applications, and Research Insights
Lobenzarit (CAS No. 63329-53-3) is a synthetic compound with a unique chemical structure that has garnered significant attention in pharmaceutical and biochemical research. Known for its immunomodulatory properties, this compound has been studied extensively for its potential therapeutic applications, particularly in autoimmune diseases. The growing interest in Lobenzarit disodium and its derivatives reflects the demand for novel treatments in chronic inflammatory conditions, a topic frequently searched in medical and scientific communities.
The molecular formula of Lobenzarit (C14H10Cl2N2O4) highlights its aromatic and heterocyclic characteristics, which contribute to its biological activity. Researchers often explore Lobenzarit sodium salt due to its enhanced solubility and bioavailability, making it a preferred form for experimental studies. Recent discussions in online forums and academic circles have focused on its mechanism of action, particularly its ability to modulate cytokine production and suppress aberrant immune responses.
One of the most searched questions about Lobenzarit is its efficacy in rheumatoid arthritis (RA) management. Studies suggest that it may inhibit the production of pro-inflammatory cytokines like IL-6 and TNF-α, aligning with current trends in targeted immunotherapy. This has led to increased interest in Lobenzarit analogs as potential alternatives to conventional disease-modifying antirheumatic drugs (DMARDs).
From a biochemical perspective, Lobenzarit interacts with cellular signaling pathways, including NF-κB and MAPK, which are critical in inflammation regulation. These pathways are frequently discussed in the context of autoimmune and metabolic disorders, making Lobenzarit research highly relevant to contemporary medical challenges. Additionally, its low toxicity profile in preclinical models has spurred investigations into its broader applications, such as in chronic inflammatory bowel diseases (IBD).
The synthesis and optimization of Lobenzarit derivatives remain an active area of research, with patents and publications highlighting novel methods to improve its pharmacokinetics. Searches for Lobenzarit solubility and stability studies reflect the practical challenges in formulating this compound for clinical use. Recent advancements in drug delivery systems, such as nanoparticle encapsulation, have further expanded its potential.
In conclusion, Lobenzarit (CAS No. 63329-53-3) represents a promising candidate for immunomodulatory therapy, with ongoing studies exploring its full therapeutic spectrum. Its intersection with trending topics like precision medicine and cytokine storms underscores its relevance in modern pharmacology. For researchers and clinicians, understanding its molecular interactions and clinical translatability is key to unlocking its future applications.
63329-53-3 (Lobenzarit) Related Products
- 91-40-7(Fenamic acid)
- 85-91-6(Methyl N-methylanthranilate)
- 87-25-2(Ethyl anthranilate)
- 61-68-7(Mefenamic acid)
- 99-05-8(3-Aminobenzoic acid)
- 99-31-0(5-Aminoisophthalic acid)
- 99-64-9(3-Dimethylaminobenzoic acid)
- 134-20-3(Methyl anthranilate)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
